Search

Intravitreal aflibercept for diabetic macular oedema

The VISTA and VIVID randomised phase 3 trial were designed to compare the efficacy and safety of intravitreal aflibercept injections versus laser photocoagulation for diabetic macular oedema (DMO). A total of 872 patients with centrally involving DMO were recruited, and...

Intravitreal triamcinolone for uveitic macular oedema

This paper from South Korea reports on a prospective, double blind, randomised clinical study designed to evaluate the additional benefit of intravitreal triamcinolone (TA) administration for noninfectious uveitic macular oedema as an adjunct therapy to systemic anti-inflammatory treatment. Patients were...

Epiretinal membranes in uveitic macular oedema

Epiretinal membrane (ERM) formation in uveitic macular oedema is a fairly common structural complication of the retina. The authors describe a retrospective case series of 104 eyes of 77 patients with uveitic macular oedema from a tertiary centre. The treatment...

Insights in resistant diabetic macular oedema

This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...

Management of diabetic macular oedema (DMO)

The authors present guidelines on current diagnostic and therapeutic procedures in the management of DMO. Fluorescein angiography (FA) and optical coherence tomography (OCT) are recommended before starting treatment to help diagnose and stage DMO, and can be repeated if there...

Macular oedema after cataract surgery in diabetic patients

The authors describe a multi-centre prospective observational study of 293 participants that underwent cataract surgery who all had diabetic retinopathy without definite central-involved macular oedema. Forty-five clinical sites took part throughout the United States. Patients were eligible if there was...

Prophylaxis for clinical macular oedema after phacoemulsification

The authors report on a retrospective cohort study looking at three different prophylaxis methods for macular oedema after cataract surgery: 1) Topical prednisolone acetate (PA) alone; 2) Topical PA in combination with non-steroidal anti-inflammatory drug (NSAID); 3) Intraoperative subconjunctival injection...

Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema

Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...

Avastin vs. Volon A for diabetic macular oedema

This prospective randomised interventional clinical trial compared 30 diabetic patients with macular oedema treated with either intravitreal injections of bevacizumab (Avastin) or triamcinolone (Volon A). One group initially received three injections of 2.5 mg Avastin in monthly intervals whilst the...

DRIL after macular oedema treatment in BRVO

The authors report the analysis of a single-site, retrospective, cross-sectional study to evaluate the association between disorganisation of the retinal inner layers (DRIL) and visual acuity (VA) after anti-VEGF treatment for macular oedema (MO) due to branch retinal vein occlusion...